Mylan will pay the Department of Justice $465 million in a settlement over its pricing and auto erotice axphicationclassification of the EpiPen through Medicaid, the pharmaceutical company announced Friday.
Mylan, which came under fire this summer for systematically hiking the price of the life-saving device, at the same time allegedly improperly classified the EpiPen as a generic drug. That led Medicaid and Medicare to both overpay for the product.
The DOJ's question centered on the EpiPen's classification through Medicaid and Medicare. The EpiPen had been classified as a non-innovator drug, affecting how the federal programs calculated rebates.
The EpiPen is not a generic, and Mylan has been criticized for failing to develop a less expensive generic version. The rules regarding a generic version of an EpiPen are different since it is the device, not the active drug, that is subject to patents.
The $465 million pre-tax settlement will cover liability claims over rebates from federal and state governments.
While separate from the outrage surrounding EpiPen pricing for consumers, the DOJ's settlement with Mylan is another hurdle for the company as it tries to recover from its public shaming. The pharmaceutical company lost celebrity endorsements and prompted inquiries from lawmakers over its hike to the price of EpiPens to as much as $600 for a two-pack, up from $50 per pen in 2007.
Mylan denied in a statement Friday that the settlement implied any wrongdoing.
"This agreement is another important step in Mylan's efforts to move forward and bring resolution to all EpiPen Auto-Injector related matters," CEO Heather Bresch said in a statement. "The agreement is in addition to the significant steps Mylan has taken in relation to EpiPen Auto-Injector over the past several weeks, including the unprecedented, pending launch of a generic version of EpiPen Auto-Injector and expansion of our patient access programs for this product. Entering into this settlement is the right course of action at this time for the company, its stakeholders and the Medicaid program."
Fragile but Fixable: The Collages of Deborah Roberts by Deborah RobertsOn Beyoncé, Beychella, and Hairography by Lauren Michele JacksonInheriting a LegacyLight Effects: On Miyoko Ito’s Abstract InventionsStaff Picks: Kendrick, Cardi Covers, and Cautionary TalesRedux: Reading About Mom by The Paris ReviewAnnouncing Our Summer Issue by The Paris ReviewEt Tu, Brute?Poetry Rx: You All Have LiedLonesome Together by Drew BratcherLilac, the Color of Fashionable FeelingsThe Book JeanTom Wolfe, 1930–2018“First of All I’m Naked”: On the Collected Poems of Michael LallyTchaikovsky’s Cure for All That Ails (the Stomach)Cooking with Émile Zola by Valerie StiversOn Becoming an American Writer by Alexander CheeThe Soviet Anthology of “Negro Poetry” by Jennifer WilsonTom Wolfe, 1930–2018On Becoming an American Writer by Alexander Chee A Formal Feeling: A Conversation with Claudia Durastanti by Mia Colleran Redux: Couples at Work by The Paris Review How to Choose Your Perfume: A Conversation with Sianne Ngai and Anna Kornbluh by Jude Stewart Parables and Diaries by The Paris Review Structure Is a Design in Light: The Notebooks of Louis I. Kahn by Louis I. Kahn Ye’s Two Words by The Paris Review NYT's The Mini crossword answers for January 19 Painting Backward: A Conversation with Andrew Cranston by Na Kim Redux: Conceptual Baggage by The Paris Review Redux: Furry Faces by The Paris Review You can now pre Best Dyson deal: Get a Dyson V15 Detect Extra for $599.99 at Best Buy How to watch the 2024 Oscar nominations livestream Announcing Our Spring Issue by Emily Stokes Walk Worthy by Eloghosa Osunde Redux: Be My Camera by The Paris Review Jamaica Kincaid Will Receive Our 2022 Hadada Award by The Paris Review Wordle today: The answer and hints for January 21 My Friend Goo by Deb Olin Unferth Cooking with Dorothy Sayers by Valerie Stivers
1.7366s , 10171.7578125 kb
Copyright © 2025 Powered by 【auto erotice axphication】,Exquisite Information Network